Eric Thomas, MD
Ophthalmology · Sioux Falls, SDNPI 1588636484
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $5,202 of the $7,116 with a category attached, or 73.1%. US Retina LLC accounts for 73.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $2,501 and has fallen 89.4% since, to $266 in 2025.
Across 58 payments — averaging $122.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$5K
- Alimera Sciences, Inc.$853
- AbbVie$312
- Apellis Pharmaceuticals, Inc.$159
- Regeneron Healthcare Solutions, Inc.$100
- Alcon$85
- plus $405 from 14 others
What the payments were for
- Food & beverage$1,91427%
- Ownership interest$5,20273%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $5,202 |
| Alimera Sciences, Inc. | 9 | $853 |
| AbbVie(2 entities) | 13 | $312 |
| Apellis Pharmaceuticals, Inc. | 3 | $159 |
| Regeneron Healthcare Solutions, Inc. | 4 | $100 |
| Alcon | 4 | $85 |
| Dutch Ophthalmic, USA | 1 | $84 |
| ANI Pharmaceuticals, Inc. | 2 | $56 |
| Genentech USA, Inc. | 4 | $55 |
| Bausch & Lomb Americas Inc. | 2 | $30 |
| Rxsight Inc | 1 | $25 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| The Cameron-ehlen Group, Inc. | 1 | $18 |
| Coherus Oncology, Inc. | 1 | $18 |
| Eyepoint US, Inc. | 1 | $18 |
| Biogen | 1 | $17 |
| Spark Therapeutics, Inc. | 1 | $17 |
| Sandoz | 1 | $14 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,116 in reported general payments places this provider in the 80th percentile of 52 ophthalmology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 176 | $8,208 |
| Atropine Sulfate | 160 | $4,933 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 140 | $905 |
| Ofloxacin | 18 | $188 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Sioux Falls
- Vance ThompsonSioux Falls$1.9M
- John BerdahlSioux Falls$1.2M
- Daniel TerveenSioux Falls$521K
- Tanner FergusonSioux Falls$49K
- Alison TendlerSioux Falls$31K
- Brent KramerSioux Falls$26K
- Jed AssamSioux Falls$18K
- Anthony MaiSioux Falls$8K
- Ryan GeraetsSioux Falls$7K
- Yujia ZhouSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.